CGEN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Compugen Ltd (CGEN) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. Despite the recent price decline, the company's strong financial performance, positive analyst outlook, and extended cash runway provide a compelling case for long-term growth potential.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), indicating an upward trend. MACD is positive but contracting, while RSI is neutral at 59.181. Key support is at 1.716, and resistance is at 2.205. The stock has a 70% chance to increase by 6.63% in the next month.
Q4 2025 earnings exceeded expectations with a revenue surge of 4477.29% YoY and a net profit turnaround.
The company extended its cash runway into 2029 through a non-dilutive agreement with AstraZeneca.
Analysts initiated coverage with a Buy rating and a $4 price target, citing strong immuno-oncology pipeline potential.
Recent price decline: -4.21% in regular market and -2.43% in post-market.
No significant insider or hedge fund activity, indicating neutral trading sentiment.
In Q4 2025, revenue surged to $67.3 million, up 4477.29% YoY. The company reported a net profit turnaround of $56.8 million and maintained a debt-free position with $145.6 million in cash. Gross margin improved to 94.75%, up 75.11% YoY.
H.C. Wainwright initiated coverage with a Buy rating and a $4 price target, highlighting the company's immuno-oncology pipeline and potential royalty streams exceeding $200M.
